um-glucose cotransporter 2 (SGLT2) is the major, and SGLT1 the minor, transporter responsible for renal glucose reabsorption. Increasing urinary glucose excretion (UGE) by selectively inhibiting SGLT2 improves glycemic control in diabetic patients. We generated Sglt1 and Sglt2 knockout (KO) mice, Sglt1/Sglt2 double-KO (DKO) mice, and wild-type (WT) littermates to study their relative glycemic control and to determine contributions of SGLT1 and SGLT2 to UGE. Relative to WTs, Sglt2 KOs had improved oral glucose tolerance and were resistant to streptozotocin-induced diabetes. Sglt1 KOs fed glucose-free high-fat diet (G-free HFD) had improved oral glucose tolerance accompanied by delayed intestinal glucose absorption and increased circulating glucagon-like peptide-1 (GLP-1), but had normal intraperitoneal glucose tolerance. On G-free HFD, Sglt2 KOs had 30%, Sglt1 KOs 2%, and WTs Ͻ1% of the UGE of DKOs. Consistent with their increased UGE, DKOs had lower fasting blood glucose and improved intraperitoneal glucose tolerance than Sglt2 KOs. In conclusion, 1) Sglt2 is the major renal glucose transporter, but Sglt1 reabsorbs 70% of filtered glucose if Sglt2 is absent; 2) mice lacking Sglt2 display improved glucose tolerance despite UGE that is 30% of maximum; 3) Sglt1 KO mice respond to oral glucose with increased circulating GLP-1; and 4) DKO mice have improved glycemic control over mice lacking Sglt2 alone. These data suggest that, in patients with type 2 diabetes, combining pharmacological SGLT2 inhibition with complete renal and/or partial intestinal SGLT1 inhibition may improve glycemic control over that achieved by SGLT2 inhibition alone.
UNDER NORMAL PHYSIOLOGICAL CONDITIONS, more than 99.5% of the glucose filtered by glomeruli in mammalian kidneys is reabsorbed by the renal tubules. Pioneering studies reported that between 83 and 98% of filtered glucose is actively transported in the proximal convoluted tubule and that almost all of the remaining glucose is actively transported later, largely in the proximal straight tubule (2, 10, 29, 47) . Further biochemical and molecular cloning studies suggested that two sodiumglucose cotransporters (SGLTs) were responsible. SGLT2, identified as the SGLT expressed in the proximal convoluted tubule, cotransports Na ϩ and glucose in a 1:1 stoichiometry. SGLT1, identified as the likely candidate for the SGLT expressed in the proximal straight tubule, cotransports Na ϩ and glucose in a 2:1 stoichiometry (15, 20, 48, 49, 52) .
Further evidence that SGLT2 plays a major role in renal glucose reabsorption comes from the finding that individuals with familial renal glycosuria (FRG; OMIM 182381) have mutations in the SGLT2 gene; urinary glucose excretion (UGE) as high as 141 g/day was reported in one subject who had inactivating mutations in both alleles (5, 33, 42, 43) . Individuals with FRG appear healthy; they do not have significant problems related either to their kidneys or, consistent with SGLT2 being expressed primarily in kidney tubules, to other organ systems (7, 52) . In contrast, individuals with two nonfunctioning alleles for SGLT1 have minimal increases in UGE but exhibit a severe intestinal malabsorption syndrome, designated glucose-galactose malabsorption (GGM; OMIM 182380), because SGLT1 is required for intestinal absorption of these sugars (28, 52) . This is consistent with much higher expression of SGLT1 in intestine than kidney (7, 52) . Other than glucose and galactose malabsorption by the intestine, no other organ system has been reported to show a phenotype due to genetic deficiency of SGLT1 (52) .
The ability of increased UGE to improve glycemic control has been known for decades (39) , and recognition that SGLT2 plays a major role in renal glucose reabsorption led many pharmaceutical companies to develop SGLT2 inhibitors as a way to improve glycemic control in patients with type 2 diabetes (T2D) (6) . Human clinical trials have repeatedly found that SGLT2 inhibitors significantly lower Hb A 1c and fasting plasma glucose and significantly improve oral glucose tolerance in patients with T2D; however, UGE is usually 30 -40% of maximum, and never greater than 60% of maximum, in these patients (8, 22, 24, 32, 46, 54) . One possible explanation for the submaximal UGE is that maximum achievable blood levels of selective SGLT2 inhibitors such as dapagliflozin are below that needed to maximally inhibit renal tubular SGLT2, but this seems unlikely because the increase in UGE plateaus at dapagliflozin doses that continue to show a linear increase in blood levels (22) . Another, more likely explanation is that SGLT1, or another glucose transporter, is present in an amount that is 1) greater than required to reabsorb all filtered glucose in healthy individuals with normal amounts of functional SGLT2, and 2) sufficient to transport a significant fraction of filtered glucose that is not reabsorbed in the absence of functional SGLT2 (17) .
Knockout (KO) mice can provide insight into the function of mammalian genes and can identify useful targets for drug development, including targets for development of diabetes drugs (30, 56) . Consistent with these observations, Sglt2 KO mice exhibit both significant glycosuria and improved glycemic control (19, 27) . Also, studies of glucose reabsorption in the proximal tubule of Sglt2 KO mice suggest that another SGLT, possibly SGLT1, compensates for SGLT2 loss by reabsorbing a significant fraction of filtered glucose (51) . In contrast, under normal physiological conditions, Sglt1 KO mice show only a slight increase in UGE but develop a severe intestinal malabsorption syndrome when fed glucose, consistent with the GGM syndrome present in SGLT1-deficient humans (13) . We chose to study Sglt1 KO and Sglt2 KO mice individually and in combination to determine the contributions of SGLT1 and SGLT2 to UGE, to confirm that Sglt2 KO mice showed improved glycemic control, and to ask whether the absence of functional SGLT1 might further improve glycemic control when combined with the absence of functional SGLT2.
METHODS
Generation of KO mice. Our approach to knocking out and phenotyping mouse orthologs of the ϳ5,000 potential drug targets in the human genome is published (3, 4, 23, 53, 55, 56) . Our Sglt2 KO mice are described (19) . Sglt1 KO mice were generated by gene trapping; methods for gene trapping in embryonic stem cells, identifying trapped genes using OmniBank Sequence Tags (OSTs), characterizing retroviral gene trap vector insertion sites, and RT-PCR analysis of KO and wild-type (WT) transcripts are published (9, 53) . Briefly, a retroviral gene trap vector was used to produce OmniBank clone OST315271, which contains an intron 1 insertion that truncates the Sglt1 gene product immediately after the first coding exon (Fig. 1, A and B). Mice heterozygous (HET) for both Sglt1 and Sglt2 were bred to generate Sglt1/Sglt2 double-KO (DKO) mice. Dipeptidyl peptidase-4 (Dpp4) KO mice were generated by homologous recombination. The Dpp4 targeting vector was derived using the Lambda KOS system as described previously (23) . This strategy resulted in deletion of the coding portion of exon 1 and all of exon 2 (Fig. 1C) . Correctly targeted clones identified and confirmed by Southern analysis (Fig.  1D ) were used to generate Dpp4 KO mice. All mice analyzed were of mixed genetic background (129/SvEvBrd and C57BL/6J). Genotyping was performed on tail DNA as described previously (57) .
Mouse husbandry. General methods for mouse care are described (9) . The Institutional Animal Care and Use Committee at Lexicon Pharmaceuticals approved all study protocols. Mice were fed either a high-fat diet (HFD; D12451, Research Diets, New Brunswick, NJ) containing 45% kcal from fat and 35% kcal from carbohydrate (18% from sucrose, 10% from maltodextrin, and 7% from cornstarch) or a glucose-free diet (G-free HFD; D08040105i, Research Diets) containing 45% kcal from fat and 35% kcal from fructose.
Glucose tolerance tests. Oral glucose tolerance tests (OGTTs) were performed on conscious, unanesthetized male mice. After an overnight fast, mice had blood collected from the retroorbital plexus at time 0 and then received, by oral gavage, 2 g glucose/kg body wt. Blood routinely collected at 30, 60, 90, and 120 min post-glucose Fig. 1 . Generation of sodium-glucose cotransporter 1 (Sglt1) and dipeptidtyl peptidase-4 (Dpp4) KO mice. A: Sglt1 KO mice were generated by gene trapping. Retroviral gene trap vector VICTR48 was used to produce clone OST315271, which contains an insertion within intron 1 of the Sglt1 gene. This mutation truncates the Sglt1 gene product immediately following the first coding exon. LTR, viral long terminal repeat; SA, splice acceptor sequence; neo, neomycin phosphotransferase gene; pA, polyadenylation sequence; Pgk, phosphoglycerate kinase-1 promoter; Btk-SD, Bruton's tyrosine kinase splice donor sequence. B: RT-PCR expression analysis of the Sglt1 transcript. Endogenous Sglt1 transcript was detected in the kidney and lung of wild-type (WT, ϩ/ϩ) mice. No endogenous Sglt1 transcript was detected in knockout (KO, Ϫ/Ϫ) tissues. Primers forward (F; 5=-CCATGGACAGTAGCACCTTGAGCCCC-3=) and reverse (R; 5=-CTGCCAGGAAGAAGCCTCCAACGGTA-3=) are complementary to Sglt1 exons 1 and 2, respectively, and amplify a product of 186 nucleotides. RT-PCR analysis using primers (actin) complementary to the mouse ␤-actin gene (acc. no. M12481) was performed in the same reaction as an internal amplification control. C: targeting strategy used to disrupt the Dpp4 locus. Homologous recombination between the pKOS-84 targeting vector and the Dpp4 gene resulted in replacement of Dpp4 exons 1 and 2 with the LacZ/Neo selection cassette. LacZ, ␤-galactosidase; D: Southern hybridization indicating proper Dpp4 gene targeting in embryonic stem cell clones. Clones 1D5, 1G8, and 1G12 were selected for blastocyst injections; Lex-1 represents untransfected embryonic stem cell DNA.
bolus was assayed for glucose with an Accu-Chek Aviva glucometer (Roche Diagnostics, Indianapolis, IN). Blood collected at 0, 30, and 60 min was also assayed for insulin (Ultra Sensitive Rat Insulin ELISA Kit, cat. no. 90060; Crystal Chem, Downers Grove, IL). Glucose and insulin time course data were converted to area-under-the curve (AUC) values by trapezoidal summation using GraphPad Prism v4.03.
As part of our phenotypic screen, OGTTs were performed on 14-wk-old male mice fed a chow diet from weaning (37) . For each mouse, OGTT blood glucose levels, measured by an automated system (Cobas Integra 400 Analyzer, Roche Diagnostics), were used to calculate a glucose AUC value. For each line, mean KO glucose AUC was calculated; this was then divided by the mean WT glucose AUC calculated by averaging the OGTT glucose AUC values of all of the WT mice pooled from the 2,986 KO lines screened, yielding a normalized glucose AUC value for each line.
As part of our phenotypic screen, OGTTs were also performed on 10-wk-old male mice fed HFD from weaning. We routinely screened eight WT and eight KO mice from each line; for the present analysis, all lines with three or more KO mice screened were included. Normalized glucose AUC values for each of the 2,489 lines studied were calculated as described above for chow-fed mice. Also, data on insulin levels measured 30 min after glucose challenge were available for 1,812 of these KO lines. For each KO line, the mean insulin level of the KO mice was calculated; this was then divided by the historical mean WT insulin level, which represented an average of mean WT insulin levels pooled from the 1,812 KO lines screened, yielding a normalized glucose-stimulated insulin concentration for each line. For analysis and presentation, these data were log-transformed to achieve a normal distribution.
Intraperitoneal glucose tolerance tests (IPGTTs) were performed exactly as were the OGTTs, except that mice received their glucose challenge as an intraperitoneal injection of 0.5 g glucose/kg body wt.
Meal challenge. A liquid meal was prepared by suspending 50 g of a low-fat diet containing 10% kcal as fat and 70% kcal as carbohydrate (36% from sucrose, 3% from maltodextrin, and 31% from cornstarch, D12450B; Research Diets) in 60 ml of water. Conscious male mice received, by oral gavage, 20 ml/kg of this suspension along with 5 ml/kg of 50% dextrose, which provided them with 9.2 g/kg carbohydrate, 2.5 g/kg protein, and 0.6 g/kg fat. Small intestinal and cecal contents collected at various times after meal challenge were assayed for glucose levels. Circulating levels of total glucagon-like peptide 1 (GLP-1) were measured by ELISA (GLP1 Total ELISA Kit, cat. no. EZGLP1T-36K; Millipore, St. Charles, MO). Glucose and total GLP-1 time course data were converted to AUC values by trapezoidal summation using GraphPad Prism v. 4.03.
Streptozotocin (STZ)-mediated induction of diabetes. Male mice were randomized to receive either vehicle (10 mM sodium citrate, pH 4.5) or vehicle containing STZ (cat. no. 572201; Calbiochem, San Diego, CA), for 5 consecutive days. After a daily 6-h fast, mice received freshly prepared vehicle or STZ by intraperitoneal injection. Measurements included blood glucose (see above), insulin (see above), and Hb A 1c (COBAS Integra 400, Roche Diagnostics). In studies involving Sglt2 KO mice, urinary tracts were collected at necropsy to search for histological evidence of urinary tract infection (UTI) and other renal histopathology, using standard pathology approaches (37) .
Metabolic cages. Mice were individually housed in metabolic cages (product MTB-0311; Nalgene, Rochester, NY) 1-3 days prior to study. To prevent contamination of urine with diet, cages were fitted with feeder cups containing G-free diet prepared as a thick paste. After acclimatization, 24-h urines were collected. Urine and serum chemistry values were measured by Cobas Integra 400 (Roche Diagnostics).
Body composition and food consumption. Body composition was estimated in conscious mice by quantitative magnetic resonance (QMR; ECHO Medical Systems, Houston, TX) as described (4).
DEXA bone mineral density (BMD) data were obtained employing standard procedures using a PIXImus2 DEXA (GE Lunar, Madison, WI). MicroCT bone scans were obtained with voxel dimensions of 8 m using a Scanco Medical CT40 (Scanco Medical, Brüttisellen, Switzerland). Food consumption was measured as described previously (4) .
Locomotor activity. Locomotor activity was measured using the Photobeam Activity System (PAS-Home Cage; San Diego Instruments, San Diego, CA). On the first day of testing, mice were individually housed in the 48.2 ϫ 26.5 cm chambers that allow free access to food and water. Mice were then exposed for the next 6 days (females) or 7 days (males) to a regular 12:12-h light-dark cycle with lights on at 7 AM and off at 7 PM.
Glomerular filtration rate. Glomerular filtration rate (GFR) was measured in conscious mice by plasma clearance kinetics of fluorescein isothiocyanate (FITC) after a single bolus intravenous injection of FITC-inulin (Sigma, St. Louis, MO), as described previously (35) . Briefly, after FITC-inulin (5%) was injected into the tail vein at a dose of 3.74 l/g body wt, ϳ10 l of plasma samples was obtained at 3, 7, 10, 15, 35, 55, and 75 min post-injection. FITC concentration was determined by fluorescence (485 nm excitation, 538 nm emission). GFR was calculated using one-and two-compartment clearance models, with the two-compartment model yielding the better fit. Mean blood glucose was calculated by averaging blood glucose levels obtained at baseline and at 75 min post-injection.
Statistics. Results are expressed as means Ϯ SD. Unless stated otherwise, comparisons between two groups were analyzed by unpaired Student's t-test, and comparisons among three or more groups were analyzed by one-way ANOVA with the Bonferroni correction for multiple comparisons. Studies reporting multiple measures of glucose, Hb A 1c, and/or insulin over time were analyzed for changes in these parameters from baseline by general linear model repeated measures two-way ANOVA performed using SAS software; the Tukey-Kramer correction was employed for multiple comparisons. In all studies, differences were considered statistically significant when P Ͻ 0.05.
RESULTS
Our high-throughput phenotypic screening of mouse KO lines found that Sglt1 KO and Sglt2 KO mice were among the most glucose tolerant of the thousands of KO lines studied, with values roughly comparable to those observed for Dpp4 KO mice (Fig. 2, A and B) . Also, Sglt1 KO and Sglt2 KO mice had insulin levels drawn 30 min after receiving the oral glucose bolus that were among the lowest observed in our phenotypic screen (Fig. 2C) .
Based on these results, both lines of KO mice were studied further. The Sglt2 KO allele was transmitted with a normal Mendelian ratio (872 WT, 1,849 HET, 871 KO) at weaning, and KO mice appeared to be as healthy as their WT littermates. When weaned onto the HFD and studied at 10 -12 wk of age, these Sglt2 KO mice had significantly improved glucose tolerance despite having insulin levels that were significantly lower than WT levels, thus confirming the OGTT phenotypic screen data (Fig. 2, D and E). Significantly improved glucose tolerance associated with lower insulin levels was also observed in older Sglt2 KO mice and in three additional independent cohorts of mice (data not shown).
Sglt2 KO mice and WT littermates next received an identical STZ challenge in an attempt to induce diabetes. STZ-treated WT mice rapidly developed diabetes, and the increased fed blood glucose (BG) and Hb A 1c levels persisted throughout the study. In contrast, STZ-treated Sglt2 KO mice showed only a slight increase in fed BG and Hb A 1c values (Fig. 3, A and B) .
Also, OGTTs performed 17 wk after STZ challenge showed that, compared with STZ-treated WT mice, STZ-treated Sglt2 KO mice had significantly lower fasting BG levels and glucose excursions (Fig. 3, D and E) . Fed and fasting insulin levels tended to be lower in the STZ-treated groups than in their vehicle controls despite having higher fed and fasting BG levels, and insulin levels did not rise in the STZ-treated groups during the OGTT, suggesting significant STZ-mediated ␤-cell (37) and in METHODS. For all histograms presented in this figure, solid points indicate actual numbers of KO lines, curved line shows the calculated curve, 1 and 2 SD are indicated by lines located outside the curve, and values for Sglt1 KO, Sglt2 KO, and Dpp4 KO mice are indicated by lines located above the curve. B: histogram of normalized glucose AUC values from OGTTs performed on 10-wk-old male mice from 2,489 KO lines maintained on high-fat diet (HFD) from weaning. Mean value was 0.98 with SD of 0.17; distribution was normal, based on Kolmogorov-Smirnov testing (P Ͻ 0.01). C: histogram of normalized glucose-stimulated insulin concentrations from OGTTs performed on 10-wk-old male mice from 1,812 KO lines maintained on HFD from weaning. Normalized levels for each KO line, calculated as described in METHODS, were log-transformed to achieve a normal distribution by Kolmogorov-Smirnov testing (P ϭ 0.05); mean value was Ϫ0.08 with SD of 0.21. D: blood glucose excursions, from OGTTs performed on 48 additional Sglt2 KO mice and 51 WT littermates aged 10 -12 wk and maintained on HFD from weaning. E: serum insulin excursions, from OGTTs performed on all mice from D that had insulin values at all time points (44 Sglt2 KO and 44 WT mice). F: blood glucose excursions, from OGTTs performed on 4 Sglt1 KO mice and 5 WT littermates aged 39 wk and maintained on HFD; blood was not collected at 90 or 120 min. Statistical comparisons in E and F were performed using the Mann-Whitney U-test. impairment in both STZ-treated groups rather than ␤-cell protection from STZ damage in Sglt2 KO mice (Fig. 3, C and  F) . When placed in metabolic cages 19 wk after STZ challenge, vehicle-treated WT mice had lower urine volumes and less total glucose in their 24-h urine collections than the other three groups, and their urine also contained less total phosphorus, magnesium, calcium, and other analytes, consistent with their lower food consumption (Table 1 ). There were no significant differences between vehicle-treated Sglt2 KO mice and WT littermates for any serum chemistry analyte. When evaluated during the last week of the study, survival rates were comparable among the four groups (Table 1) . Histological examination revealed no evidence of infection or diabetesrelated inflammation in the urinary tracts of these mice, with the exception of one STZ-treated Sglt2 KO mouse with candidal balanoposthitis. Similar results were noted in a second cohort of Sglt2 KO and WT mice, except that no infections were observed in the 13 Sglt2 KO mice studied (data not shown).
Like the Sglt2 KO allele, the Sglt1 KO allele was transmitted with a normal Mendelian ratio (782 WT, 1,642 HET, 844 KO) at weaning. Interestingly, the Sglt1 KO mice had normal body composition at weaning (Table 2 ) despite ingesting glucose and galactose-containing maternal milk for 3 wk. After being weaned onto a glucose-containing HFD, Sglt1 KO mice began to differ from WT and HET littermates by appearing ill with decreased weight gain (Fig. 4A) and increased mortality, which is consistent with the reluctance of Sglt1 KO mice, but not HET or WT littermates, to eat glucose-containing HFD (Fig. 4B) . Cecal distention was present in many Sglt1 KO mice at necropsy. An OGTT performed on 39-wk-old Sglt1 KO mice fed HFD from weaning showed no increase in circulating glucose (Fig. 2F) , consistent with the finding that, 30 min after this glucose challenge, insulin levels had increased only 0.26 Ϯ 0.13 ng/ml in the SGLT1 KO mice compared with 4.2 Ϯ 4.2 ng/ml in WT littermates (P Ͻ 0.01, Mann-Whitney U-test). Based on these findings, mice lacking Sglt1 were maintained on G-free HFD with fructose as the sole carbohydrate source. Sglt1 KO, HET, and WT littermates developed normally on this diet, but Sglt1 KO mice and, to a lesser extent Sglt1 HET mice, responded to an oral glucose challenge with increased levels of intestinal glucose and circulating total GLP-1 (Fig. 4 , C-E). When 13-to 20-wk-old Sglt1 KO and WT mice, fed G-free HFD from weaning, were challenged with STZ, they showed comparable increases in fed BG and Hb A1c; furthermore, an IPGTT performed 4 wk after STZ challenge showed Data arepresented as means Ϯ SD; n, number of mice. DKO, double knockou; G-free, glucose free; HFD, high-fat diet. *Different from DKO, P Ͻ 0.05; **different from WT and DKO, P Ͻ 0.05. that vehicle-treated Sglt1 KO and WT mice had comparable fasting BG and glucose excursions and that STZ-treated Sglt1 and WT mice showed comparable impairment of fasting BG, glucose excursions, and insulin excursions (data not shown).
To evaluate the contributions of SGLT1 and SGLT2 to renal glucose reabsorption, we crossed Sglt1 and Sglt2 HET mice to generate cohorts with WT, Sglt1 KO, Sglt2 KO, and Sglt1/ Sglt2 DKO mice. DKO mice were as abundant as WT mice at weaning (131 WT, 157 Sglt1 KO, 150 Sglt2 KO, 127 DKO) and appeared healthy when maintained on G-free HFD. When mice aged 18 -28 wk were placed in metabolic cages, UGE was highest in DKO mice, measuring 747 Ϯ 224 mg/day in Fig. 4 . Effect of glucose-containing diet on body weight, food consumption, intestinal glucose levels, and circulating total glucagon-like peptide-1 (tGLP-1) levels in Sglt1 heterozygous (HET) and Sglt1 KO mice. A: body weights of chow-fed WT (n ϭ 4), Sglt1 HET (n ϭ 4), and Sglt1 KO (n ϭ 7) mice between 2 and 16 wk of age. B: daily food intake was measured in 12-wk-old WT (n ϭ 8), Sglt1 HET (n ϭ 10), and Sglt1 KO (n ϭ 13) mice fed their maintenance G-free HFD on study days 1 and 2 and then fed glucose-containing HFD on study days 3 and 4. C: 28-to 33-wk-old WT, Sglt1 HET, and Sglt1 KO mice maintained on G-free HFD from weaning were challenged with a glucose-containing meal at time 0 as described in METHODS. The amount of glucose present in the small intestine (Int) at time 0, and at 1, 2, 3, and 6 h after meal challenge, was measured in 4 -7 mice/genotype at each time point. Time course data for small intestinal glucose were converted to AUC values for each genotype as described in METHODS. D: cecal glucose data from the same mice studied in C. E: serum tGLP-1 data from the same mice studied in C. males and 449 Ϯ 158 mg/day in females (Fig. 5) . UGE was negligible both in WT mice, measuring Ͻ1 mg/day, and in Sglt1 KO mice, measuring ϳ2% of DKO values in males and females. Of interest, UGE of Sglt2 KO mice measured only ϳ30% of DKO values in males and females, suggesting that SGLT1 has the capacity to reabsorb ϳ70% of filtered glucose normally reabsorbed by SGLT2. No clinically significant differences were noted among the four groups for any blood chemistries, although BG levels did trend lower in DKO mice (data not shown). Urine volumes were greater in Sglt2 KO and DKO mice relative to WT and Sglt1 KO littermates, and male DKO mice showed modest but at times significant increases in urine calcium, magnesium, phosphorus, sodium, chloride, potassium, and urea compared with male WT littermates ( Table 3 ).
The increased UGE observed in DKO mice could have resulted from greater amounts of filtered glucose secondary to markedly increased blood glucose levels and/or GFR in DKO mice. However, we found no evidence for this in a separate study, wherein seven male DKO mice and nine male WT littermates showed GFR values of 289 Ϯ 152 and 185 Ϯ 90 l/min, respectively (P Ͼ 0.05), with mean BG values during the GFR study of 88 Ϯ 28 and 129 Ϯ 15 mg/day, respectively (P Ͻ 0.01). These data suggest that comparable amounts of glucose were filtered by DKO and WT mice during the course of the GFR study, and that changes in GFR and mean BG cannot account for the markedly increased UGE observed in DKO mice.
To determine whether the increased UGE of DKO mice improved their glucose homeostasis relative to that of Sglt2 Fig. 5 . Twenty-four-hour urinary glucose excretion (UGE) of Sglt1 KO, Sglt2 KO, double-KO (DKO), and WT littermate mice. UGE was measured in 18-to 28-wk-old WT, Sglt1 KO, Sglt2 KO, and DKO mice placed in metabolic cages and studied over 24 h; see METHODS for details. A: male mice. B: female mice. For each group of mice, the 24-h mean Ϯ SD values for 24-h UGE, in mg, is presented below the scatter plot of individual data points. (Fig. 6B) . Fasting BG Ͻ 60 mg/dl was not observed in Sglt2 KO mice but was often observed in DKO mice; however, DKO mice always appeared healthy, including during this fast. DKO mice also showed significantly improved glucose tolerance and trends toward lower insulin levels 30 and 60 min after glucose challenge compared with WT and Sglt2 KO mice (Fig. 6, C  and D) . These findings were confirmed in a second study (data not shown). Consistent with the trend toward lower BG levels in DKO mice during the metabolic cage study, and significantly lower BG levels in DKO mice relative to WT littermates during the GFR study, BG levels were significantly lower during most of a 10-h interval of the light cycle in an independent cohort of DKO mice relative to levels measured in WT, Sglt1 KO, and Sglt2 KO littermates (Fig. 6E) . Body composition data from multiple cohorts of Sglt2 KO and WT mice fed HFD failed to show a body weight, body fat, or lean body mass phenotype for Sglt2 KO mice despite a significant loss of calories in the form of urinary glucose (Fig. 7A and Table 2 ). Absence of a lean phenotype may be explained, at least in part, by increased food consumption of Sglt2 KO mice (Table 1) . A 25-day pair-feeding study supported this finding; ad libitum-fed Sglt2 KO mice ate more than WT littermates and Sglt2 KO mice pair-fed to the WT mice, and only the pair-fed Sglt2 KO mice had significantly lower body weight and body fat than the WT mice (Fig. 7, B-D) . In addition, DEXA and microCT analyses sug- Fig. 6 . Improved glycemic control in DKO mice. An IPGTT performed on 24-to 27-wk-old WT (n ϭ 17), Sglt2 KO (n ϭ 16), and DKO (n ϭ 27) mice was analyzed for fasting blood glucose levels (A), fasting serum insulin levels (B), glucose excursions (C), and insulin excursions (D). E: fed blood glucose levels were measured throughout the light cycle in 21-to 25-wk old WT (n ϭ 10), Sglt1 KO (n ϭ 7), Sglt2 KO (n ϭ 7), and DKO (n ϭ 10) mice.
gested that both Sglt1 KO and Sglt2 KO mice had normal bone mass relative to WT littermates (Table 4) .
Male DKO mice had significantly lower body weight and fat than male WT or Sglt1 KO mice and tended to have lower body weight and fat than male Sglt2 KO mice despite food consumption that was significantly greater in DKO mice than in WT, Sglt1 KO, or Sglt2 KO littermates (Table 2 ). Female DKO mice had comparable levels of body weight, body fat, and food consumption to those of female WT, Sglt1 KO, and Sglt2 KO littermates (Table 2) . Similar body weight and fat data were obtained from an independent cohort of male and female mice (data not shown). Locomotor activity did not differ significantly among DKO, Sglt2 KO, Sglt1 KO, and WT mice (Fig. 7, E and F) .
DISCUSSION
Studies presented here show improved glycemic control in Sglt1 KO and Sglt2 KO mice as well as the viability and improved glycemic control of Sglt1/Sglt2 DKO mice. The findings of lower glucose and insulin levels during OGTTs in Fig. 7 . Body composition, food consumption, and activity studies. A: mean body fat data from a single cohort of male Sglt2 KO (n ϭ 19) and WT (n ϭ 18) mice, and female Sglt2 KO (n ϭ 12) and WT (n ϭ 10) mice, measured at 6, 12, 18 and 24 wk of age. Complete body composition data on these mice at 12 wk of age can be found in Table 2 . B: mean daily food consumption of ad libitum-fed Sglt2 KO mice (n ϭ 9), ad libitum-fed WT littermates (n ϭ 20), and Sglt2 KO mice pair-fed (PF) to the WT mice (n ϭ 10); these male mice were 7 wk old at the start of the study. After 25 days, the 3 groups of mice were evaluated for change in body weight (C) and change in body fat (D). E: mean total ambulatory counts/cycle, averaged over 7 light cycles and 7 dark cycles, for male WT (n ϭ 10), Sglt1 KO (n ϭ 8), Sglt2 KO (n ϭ 7), and DKO (n ϭ 10) mice; mice were 38 -42 wk old at the start of the 7 day study. F: mean total ambulatory counts/cycle, averaged over 6 light cycles and 6 dark cycles, for female WT (n ϭ 10), Sglt1 KO (n ϭ 8), Sglt2 KO (n ϭ 18), and DKO (n ϭ 8) mice; mice were 39 -43 wk old at the start of the 6-day study.
follow-up cohorts of Sglt1 and Sglt2 KO mice confirm OGTT data for Sglt1 KO and Sglt2 KO mice from our high-throughput phenotypic screen. Along with screen data for Dpp4 KO mice, these results support the hypothesis that high-throughput OGTT screening can identify potential targets for diabetes therapeutics (3). Our findings of improved glucose tolerance, along with lower fasting glucose and insulin levels, in Sglt2 KO mice confirm the findings of others studying either our Sglt2 KO mice (19) or Sweet Pee (sp/sp) mice that are homozygous for the inactivating sp mutation in the Sglt2 gene (27) . Also, our finding that Sglt2 KO mice were resistant to the development of diabetes after STZ challenge confirms similar findings in STZ-treated sp/sp mice (27) .
The improved glucose tolerance of Sglt1 KO mice is due to their inability to absorb glucose in the small intestine, because glucose tolerance is normal when Sglt1 KO mice fed G-free HFD are challenged with an intraperitoneal bolus of glucose. Sglt1 KO mice appear healthy at weaning, probably because the intestine of suckling rodents has increased permeability to sugars and other nutrients (16) . However, once weaned, Sglt1 KO mice exhibit decreased food consumption, poor weight gain, and increased mortality soon after being fed glucose-containing HFD; this constellation of findings is reminiscent of the GGM phenotype present in humans lacking functional SGLT1 and in an independent line of Sglt1 KO mice (13, 52) . Consistent with these findings, Sglt1 KO mice fed G-free HFD have very high levels of intestinal glucose after oral glucose challenge. Of interest, 1) this increase in intestinal glucose is accompanied by a dramatic rise in circulating total GLP-1; 2) Sglt1 HET mice also have high levels of intestinal glucose and circulating total GLP-1 after oral glucose challenge; and 3) unlike Sglt1 KO mice, Sglt1 HET mice fed glucosecontaining HFD from weaning show no aversion to this diet and grow normally. These observations in mice 1) are consistent with findings in humans treated with LX4211, a dual SGLT1/SGLT2 inhibitor that increases UGE by inhibiting renal tubular SGLT2 and increases circulating levels of GLP-1 and PYY, without increasing intestinal side effects, most likely by partially inhibiting intestinal SGLT1 (54); and 2) suggest a therapeutic window for pharmacological SGLT1 inhibition within which glycemic control is improved without the intestinal side effects that accompany complete genetic loss of SGLT1 function. Increasing GLP-1 levels is desirable, because therapies that increase circulating GLP-1 activity, either by providing long-acting GLP-1 analogs or by inhibiting DPP4-mediated GLP-1 metabolism, improve glycemic control in patients with T2D (38, 44) . On the basis of the finding that total GLP-1 was lower 5 min after oral glucose challenge in Sglt1 KO mice, Gorboulev et al. (13) concluded that SGLT1 was needed to trigger glucose-dependent GLP-1 secretion, a conclusion supported by in vitro studies performed using primary L cells (36) . These data are consistent with a study showing that, after exposure of the intestine to the SGLT inhibitor phlorizin, intestinal GLP-1 release was decreased 5 min after intraluminal glucose challenge (31) . Importantly, neither study reported GLP-1 levels after the 5-min time point. In contrast, we found that the major effect of a glucose-containing meal is to increase, for several hours, total GLP-1 levels in Sglt1 KO and HET mice (present study), and total and active GLP-1 levels, and total PYY levels in LX4211-treated humans with T2D (54). It is possible that SGLT1 mediates a pathway leading to early release of intestinal GLP-1 and that a fall in GLP-1 levels occurred soon after the meal challenge and before blood sampling began in our Sglt1 KO mice and in LX4211-treated patients with T2D (54). However, even if this occurs, more dominant mechanisms must exist to mediate the prolonged increase in intestinal peptide levels observed in Sglt1 KO mice and in LX4211-treated humans with T2D (54) . In one likely scenario, glucose not absorbed by the SGLT1-deficient small intestine is fermented in the large intestine to short-chain fatty acids, which are potent stimuli for intestinal GLP-1 and PYY secretion (26, 58) . In any case, a prolonged increase in circulating GLP-1 levels is the physiologically relevant consequence of glucose challenge to a small intestine deficient in functional Sglt1.
SGLT2, and to a lesser extent SGLT1, are the transporters that reabsorb glucose in the mammalian kidney (5, 13, 15, 17, 19, 20, 27, 33, 42, 43, 48, 49, 51, 52) . Based on the facts that 1) GFR values did not differ significantly between our Sglt2 KO and WT mice (51), 2) GFR values were a statistically insignificant 35% higher in DKO relative to WT mice, 3) fed BG levels for DKO mice averaged ϳ20% lower than for Sglt2 KO and WT mice, and 4) UGE ϭ mean daily GFR ϫ mean daily BG level, we conclude that differences in UGE among WT, Sglt2 KO, and DKO mice are due to differences in tubular glucose reabsorption, not in the amount of glucose filtered at the glomerulus. DKO mice showed the greatest UGE, measuring 747 Ϯ 224 mg/day in males and 449 Ϯ 158 mg/day in females. In contrast, the 24-h UGE of Sglt1 KO mice was only ϳ2% of DKO values, indicating that there was enough renal tubular SGLT2 present to reabsorb essentially all glucose filtered by these mice. Importantly, the 24-h UGE of Sglt2 KO mice was only ϳ30% of DKO values, a finding that supports two predictions: 1) that another renal tubular SGLT is present in amounts sufficient to partially compensate for loss of SGLT2 (51), and 2) that this SGLT is SGLT1 (17) . This finding could also explain why compounds that achieve what appear to be sufficiently high blood levels, and are selective and highly potent inhibitors of SGLT2 but not SGLT1 in the renal tubule, fail to increase 24-h UGE to more than 60% of maximum in patients with T2D (8, 22, 24, 32, 46, 54) : in humans as in mice, there may be enough tubular SGLT1 to significantly compensate for the decrease in functional SGLT2; the same explanation can account for why individuals with complete loss of functional SGLT2 due to inactivating mutations of both SGLT2 alleles have a wide range of 24-h UGE values that seem to be less than maximum (5, 33, 42, 43, 52) . Although one individual is said to completely lack tubular glucose reabsorption, the published data suggest 24-h UGE values that are ϳ80% of maximum (33, 43) . Consistent with these observations, our Sglt2 KO mice had a wide range of 24-h UGE values that extended as high as 453 mg/day in males and 341 mg/day in females and represent 61 and 76%, respectively, of maximum where maximum is represented by mean DKO values. Nevertheless, it is important to remember that, despite their inability to completely inhibit renal glucose reabsorption, SGLT2 inhibitors consistently provide a significant improvement in the glycemic control of patients with T2D in multiple independent clinical trials (8, 22, 24, 32, 46, 54) .
Deficiency of both Sglt1 and Sglt2 together provided improved glycemic control over deficiency of Sglt2 alone. Compared with Sglt2 KO mice, DKO mice had lower fed and fasting BG levels. The striking fall in fasting BG in nondiabetic DKO mice suggests that inhibiting both SGLT1 and SGLT2 in the kidney may be a powerful way to lower fasting BG levels that are often markedly elevated in patients with poorly controlled T2D; in these patients, decreases in fasting BG correlate well with decreases in Hb A 1c (41) . The fact that fasting was often associated with asymptomatic hypoglycemia in DKO mice but not in Sglt2 KO mice is consistent with the finding that hypoglycemia is rare when patients with T2D are treated with LX4211 and other compounds that inhibit renal tubular SGLT2 but not renal tubular SGLT1 (6, 8, 22, 24, 32, 46, 54) , but it also suggests that an increased risk of hypoglycemia may accompany decreased food intake in patients with T2D who are being treated with compounds that inhibit both renal tubular SGLT1 and SGLT2. The improved glycemic control observed in DKO mice compared with Sglt2 KO littermates is likely due to the significantly increased UGE of DKO mice. It is not due to increases in intestinal GLP-1 release, because all DKO cohorts were fed a glucose-free diet, and dietary glucose is required to allow the increases in intestinal glucose that 1) result from intestinal SGLT1 inhibition and 2) are associated with intestinal GLP-1 release. Also, when fed a glucose-free diet, mice lacking SGLT1 alone do not display improved glycemic control, or increased UGE, relative to WT littermates.
Body weight, fat, and LBM values were comparable between WT and Sglt2 KO littermates. The Sglt2 KO mice were hyperphagic, and a pair-feeding study found that the hyperphagia partially compensated for calories lost in the form of urinary glucose. Others studying our Sglt2 KO mice before or after backcross to the db/db background found no consistent body weight, body fat, or food consumption phenotypes (19) , but one small cohort of mice with the Sglt2 sp mutation did show significantly lower body weights in sp/sp and sp/ϩ mice compared with WT (27) . These inconsistent results are reminiscent of the ability of selective SGLT2 inhibitors to lower body weight in some (11, 21, 34, 50) , but not all (1, 11, 12, 14, 45) , rodent models of T2D. In contrast, SGLT2 inhibitors lower body weight consistently in patients with T2D (6, 46, 54) . Unlike Sglt2 KO mice or female DKO mice, male DKO mice had lower body weight and fat than male WT littermates. This was likely due to their increased UGE, which was at least 67% higher than the UGE of Sglt2 KO or female DKO mice and was apparently beyond the ability of the male DKO mice to fully compensate for with increased food intake. Locomotor activity did not differ among DKO, Sglt1 KO, Sglt2 KO, and WT mice, which fails both to explain the lower weight of male DKO mice and to confirm a report of significantly increased locomotor activity in Sglt2 KO mice (19) .
Our Sglt2 KO mice had survival rates comparable to those of WT mice whether or not they received STZ. This contrasts with the higher mortality rate of STZ-treated sp/sp and sp/ϩ mice, which was attributed, in part, to an increase in severe UTIs (27) . We did not observe a UTI in any Sglt2 KO mouse that received STZ or vehicle, but we did observe candidal balanoposthitis in one STZ-treated Sglt2 KO mouse, consistent with the moderate increase in perineal yeast infections and very modest increase in UTIs found in patients with T2D treated with the selective SGLT2 inhibitor dapagliflozin (46) . Also, increased urine calcium, magnesium, and phosphorus levels reported in sp/sp mice were unlikely to contribute to increased sp/sp mortality. Our data suggest that these increases were not always present and when present were more likely to reflect a normal response to the hyperphagia of Sglt2 KO mice than to reflect net losses. Importantly, many sp/sp mice received a second round of STZ treatment (27) , but no data were presented to refute the possibility that increased mortality was related to increased STZ exposure.
It is conceivable that the renal tubular mechanism of action of SGLT2 inhibitors might alter calcium and phosphate homeostasis and bone mass, and early data showed small increases in serum magnesium, phosphate, and parathyroid hormone when patients with T2D were treated with the selective SGLT2 inhibitor dapagliflozin (24) . However, we did not find any evidence of decreased bone mass in SGLT2 KO or SGLT1 KO mice at ϳ1 yr of age. These data are consistent with the absence of changes in bone mass, bone formation markers, and bone resorption markers in patients with T2D after ϳ1 yr of dapagliflozin treatment (25) .
The data presented here are consistent with the ability of selective SGLT2 inhibitors to improve glycemic control in preclinical models of T2D and in patients with T2D. The data also suggest potential benefits for compounds that inhibit SGLT1 in addition to SGLT2: 1) partial deficiency of intestinal SGLT1 in Sglt1 HET mice was associated with increased total GLP-1 levels but not with gastrointestinal side effects, supporting the clinical data from patients with T2D treated with the dual inhibitor LX4211 (54) that inhibits renal tubular SGLT2 and partially inhibits intestinal SGLT1; and 2) deficiency of renal SGLT1 in addition to SGLT2, as occurs in DKO mice, was associated with significantly increased UGE and improved glycemic control compared with mice with deficiency of SGLT2 alone. These observations support attempts to develop, as treatments for T2D, compounds that are restricted to the intestinal tract where they partially inhibit intestinal SGLT1 (18, 40) . Furthermore, compounds that inhibit both renal tubular SGLT1 and SGLT2, with or without the additional ability to inhibit intestinal SGLT1, may have potential as therapeutic agents for patients with T2D.
